Tag Archives: Luna Diabetes

AZ Q2 ’26 Earnings; Ex-Dexcom Executive Joins Luna Diabetes; Ascletis Preclinical Tri-Agonist Data; Ionis Pediatric Olezarsen Study; Lexicon Ph3 Sota Study; Veru Ph2b Enobosarm Study

A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Daprodustat NDA Accepted by FDA; Sean Saint Looks to Do It Again; April 19-22 CHMP Agenda; J&J Q1 ’22 Earnings Update

Several cardiometabolic-related news items have recently been observed: GSK announced FDA accepted the daprodustat NDA for the treatment of patients with anemia due to CKD; Sean Saint has started a new company called Luna Diabetes (view website); the CHMP agenda for this month’s meeting (April 19-22) has been released; and J&J hosted their Q1’ 22 earnings call (press release; slides). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Already a member? Log in here